Upamostat, also known as Mesupron and WX-671, is an orally bioavailable second-generation serine protease inhibitor prodrug derived from 3-amidinophenylalanine. It targets the human urokinase plasminogen activator (uPA) system and exhibits potential antineoplastic and antimetastatic properties. After oral administration, the serine protease inhibitor WX-671 is converted into its active form, Nalpha-(2,4,6-triisopropylphenylsulfonyl)-3-amidinophenylalanine-4-ethoxycarbonylpiperazinylamide (WX-UK1), which inhibits multiple serine proteases, especially uPA, potentially hindering tumor growth and metastasis.
Molekulargewicht:
727.89
CAS Nummer:
[1191101-19-5]
Formel:
C32H49N5O10S2
T202568
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
